|Title:||20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof|
|Abstract:||Steroid compounds of the 20-spiroxane series and their analogues having an open ring E of the formula, ##STR1## in which --A--A-- represents the group --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, R.sup.1 represents hydrogen, and R.sup.2 represents an .alpha.-oriented lower alkoxycarbonyl radical, or R.sup.1 and R.sup.2 together represent an .alpha.- or a .beta.-oriented methylene radical, --B--B-- represents the group --CH.sub.2 --CH.sub.2 -- or an .alpha.- or .beta.-oriented group ##STR2## X represents two hydrogen atoms or oxo, Y.sup.1 and Y.sup.2 together represent the oxygen bridge --O--, or Y.sup.1 represents hydroxy, and Y.sup.2 represents hydroxy, lower alkoxy or, if X represents H.sub.2, also lower alkanoyloxy, and salts of compounds in which X represents oxo and Y.sup.2 represents hydroxy, are distinguished as effective aldosterone-antagonists with minimal side-effects and, for that reason, are especially suitable for the treatment of all forms of hyperaldosteronism.|
|Inventor(s):||Grob; Jurgen (Giebenach, CH), Kalvoda; Jaroslav (Binningen, CH)|
|Assignee:||Ciba Geigy Corporation (Ardsley, NY)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Switzerland||1981/83||Apr 13, 1983|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.